Technologies
PDF


WARF: P150029US02

New System for Producing Fungal Secondary Metabolites


INVENTORS -

Nancy Keller, Philipp Wiemann

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a genetic expression system that enables researchers to control the production of novel secondary metabolites in fungus.
OVERVIEWFungi produce a variety of chemical compounds called secondary metabolites that possess useful pharmaceutical properties. These compounds are invaluable platforms for developing front-line drugs. They have been harnessed to fight bacterial infections, cancer and lipid disorders among other applications (e.g., the antibiotic penicillin and the cholesterol drug lovastatin are types of secondary metabolites).

Their therapeutic potential is truly outstanding – more than half of the 1,500 fungal secondary metabolites analyzed between 1993 and 2001 have shown antibacterial, antifungal or antitumor activity. However, a majority of fungal species may have untapped potential. This is because some fungi cannot be cultured under laboratory conditions or their secondary metabolites are chemically complicated, hindering traditional synthesis methods.
THE INVENTIONUW–Madison researchers have developed a new system for producing fungal secondary metabolites using test plasmids and a genetically modified strain of Aspergillus nidulans (TPMW2.3). The strain begins producing secondary metabolites when a gene promoter in the plasmid is triggered by culture conditions. This allows researchers to induce or repress production.
APPLICATIONS
  • Production of secondary metabolites, fungal toxins
KEY BENEFITS
  • Easy genetic solution to control the production of novel secondary metabolites
  • Could produce higher yields of antifungal metabolites (by delaying gene expression until late in the growth cycle of cultured fungi)
  • A. nidulans is well known, easy to manipulate and non-pathogenic.
STAGE OF DEVELOPMENTThe researchers have used the new system to produce a secondary metabolite found naturally in a different Aspergillus strain, A. terreus.
Contact Information
For current licensing status, please contact Mark Staudt at mstaudt@warf.org or 608-960-9845.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.